229 related articles for article (PubMed ID: 24401107)
1. Sex differences in HIV outcomes in the highly active antiretroviral therapy era: a systematic review.
Castilho JL; Melekhin VV; Sterling TR
AIDS Res Hum Retroviruses; 2014 May; 30(5):446-56. PubMed ID: 24401107
[TBL] [Abstract][Full Text] [Related]
2. Are there differences in disease progression and mortality among male and female HIV patients on antiretroviral therapy? A meta-analysis of observational cohorts.
Abioye AI; Soipe AI; Salako AA; Odesanya MO; Okuneye TA; Abioye AI; Ismail KA; Omotayo MO
AIDS Care; 2015; 27(12):1468-86. PubMed ID: 26695132
[TBL] [Abstract][Full Text] [Related]
3. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.
Hung CC; Chen MY; Hsiao CF; Hsieh SM; Sheng WH; Chang SC
AIDS; 2003 Dec; 17(18):2615-22. PubMed ID: 14685055
[TBL] [Abstract][Full Text] [Related]
4. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review.
Nicastri E; Leone S; Angeletti C; Palmisano L; Sarmati L; Chiesi A; Geraci A; Vella S; Narciso P; Corpolongo A; Andreoni M
J Antimicrob Chemother; 2007 Oct; 60(4):724-32. PubMed ID: 17715125
[TBL] [Abstract][Full Text] [Related]
5. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
[TBL] [Abstract][Full Text] [Related]
7. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
Chang LW; Harris J; Humphreys E
Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
9. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users.
Mehta SH; Lucas G; Astemborski J; Kirk GD; Vlahov D; Galai N
AIDS Care; 2007 May; 19(5):637-45. PubMed ID: 17505924
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.
Chen TY; Ding EL; Seage Iii GR; Kim AY
Clin Infect Dis; 2009 Nov; 49(10):1605-15. PubMed ID: 19842982
[TBL] [Abstract][Full Text] [Related]
11. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review.
Hart JE; Jeon CY; Ivers LC; Behforouz HL; Caldas A; Drobac PC; Shin SS
J Acquir Immune Defic Syndr; 2010 Jun; 54(2):167-79. PubMed ID: 20375848
[TBL] [Abstract][Full Text] [Related]
12. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
13. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients.
Antiretroviral Therapy Cohort Collaboration
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):607-15. PubMed ID: 18043315
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes.
Chung MH; Richardson BA; Tapia K; Benki-Nugent S; Kiarie JN; Simoni JM; Overbaugh J; Attwa M; John-Stewart GC
PLoS Med; 2011 Mar; 8(3):e1000422. PubMed ID: 21390262
[TBL] [Abstract][Full Text] [Related]
15. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.
Mocroft A; Madge S; Johnson AM; Lazzarin A; Clumeck N; Goebel FD; Viard JP; Gatell J; Blaxhult A; Lundgren JD
J Acquir Immune Defic Syndr; 1999 Dec; 22(4):369-78. PubMed ID: 10634199
[TBL] [Abstract][Full Text] [Related]
16. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
Seminari E; De Silvestri A; Boschi A; Tinelli C
AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
[TBL] [Abstract][Full Text] [Related]
17. [Survival status and influencing factors of HIV/AIDS on highly active anti-retrovial therapy in Shandong province].
Zhang N; Zhu XY; Wang GY; Tao XR; Wang N; Kang DM
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Jan; 40(1):74-78. PubMed ID: 30669735
[No Abstract] [Full Text] [Related]
18. Effectiveness of antiretroviral treatment in a South African program: a cohort study.
Fairall LR; Bachmann MO; Louwagie GM; van Vuuren C; Chikobvu P; Steyn D; Staniland GH; Timmerman V; Msimanga M; Seebregts CJ; Boulle A; Nhiwatiwa R; Bateman ED; Zwarenstein MF; Chapman RD
Arch Intern Med; 2008 Jan; 168(1):86-93. PubMed ID: 18195200
[TBL] [Abstract][Full Text] [Related]
19. Kidney and liver organ transplantation in persons with human immunodeficiency virus: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(4):1-56. PubMed ID: 23074407
[TBL] [Abstract][Full Text] [Related]
20. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
